Combining Fruquintinib and Venetoclax for Colorectal Cancer Treatment
Author Information
Author(s): ZHANG WEI, WANG WEICHENG, WANG RUI, HAN XIAO, ZHU LIJUN, GUO WENJIE, GU YANHONG
Primary Institution: The First Affiliated Hospital of Nanjing Medical University
Hypothesis
Does the combination of fruquintinib and venetoclax enhance the treatment efficacy for colorectal cancer?
Conclusion
The combination of venetoclax and fruquintinib significantly enhances the treatment effects on colorectal cancer by improving vascular normalization and modulating the tumor immune microenvironment.
Supporting Evidence
- The combination of fruquintinib and venetoclax led to a 68.76% reduction in tumor weight compared to controls.
- Venetoclax enhanced the anti-angiogenic effects of fruquintinib.
- Immunohistochemical analysis showed lower levels of tumor proliferation markers in the combination group.
- Flow cytometry indicated increased activation of immune cells in the tumor microenvironment.
Takeaway
Using two medicines together, fruquintinib and venetoclax, helps fight colorectal cancer better than using just one of them.
Methodology
A colon cancer mouse model was developed, and various techniques including immunohistochemistry, Western blot analysis, and flow cytometry were used to evaluate the treatment effects.
Participant Demographics
Seven-week-old BALB/c mice were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website